Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stelian Serban

Anesthesiology Edison, NJ Medical Doctor

NPI 1114902467 CMS profile 141373

10 Parsonage Rd Ste 208, Fl 6, Edison, NJ 08837

Open in the dashboard

General payments

$2,759

39 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stelian Serban of Edison, NJ is reported in the CMS Open Payments database as having received $2,759 across 39 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,052 18
2024 General $879 9
2023 General $291 5
2022 General $194 3
2021 General $148 1
2020 General $132 1
2019 General $63 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stelian Serban
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Stelian Serban were reported at $1,052. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Stelian Serban Anesthesiology median Middle half National median
2019 $63 $72 $23–$151 $163
2020 $132 $36 $17–$120 $114
2021 $148 $49 $21–$135 $132
2022 $194 $52 $22–$144 $149
2023 $291 $53 $23–$143 $160
2024 $879 $55 $25–$150 $164
2025 $1,052 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Nevro Corp. $1,142 13 payments
  2. Abbott Laboratories $624 8 payments
  3. Medtronic, Inc. $223 2 payments
  4. BIOTRONIK NRO, Inc. $212 3 payments
  5. Boston Scientific Corporation $175 3 payments
  6. SPR Therapeutics, Inc $145 2 payments
  7. Nalu Medical, Inc. $101 1 payment
  8. Globus Medical, Inc. $36 2 payments
  9. AbbVie, Inc. $34 1 payment
  10. Collegium Pharmaceutical, Inc. $19 1 payment
  11. Other $47 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,276 33 payments
  2. Travel and Lodging $482 6 payments
Products named General payments · program years 2019–2025
  1. Senza $619 7 payments
  2. PROCLAIM $482 6 payments
  3. Omnia $328 3 payments
  4. Senza Spinal Cord Stimulation System $195 3 payments
  5. General - Pain Management $175 3 payments
  6. Prospera Not Applicable $160 2 payments
  7. SPRINT PNS System $145 2 payments
  8. INFINITY $123 1 payment
  9. Nalu Neurostimulation System $101 1 payment
  10. Prospera Not Applicable $52 1 payment
  11. Other $179 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 56 drugs

Part D claims

3,349

Median for Anesthesiology: 322

Drug cost

$391,357

Median for Anesthesiology: $8,738

Branded share of claims

19.3%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 78 $258,454
Diclofenac Sodium Generic 104 $34,573
Oxycodone Hcl Generic 552 $19,394
Xtampza Er Oxycodone Myristate Brand 13 $14,234
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 328 $11,529
Fentanyl Generic 34 $5,229
Lidocaine Generic 59 $4,612
Naloxone Hcl Generic 56 $3,664
Pregabalin Generic 137 $3,563
Doxepin Hcl Generic 32 $3,336

The 10 drugs with the highest cost, of 56 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$144,360

Of which drugs: $4,987

Medicare patients

250

Average age 71

Services billed

8,677

148 women, 102 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 74%
High blood pressure 69%
Diabetes 38%
Depression 34%
Ischemic heart disease 33%
Osteoporosis 24%
Chronic kidney disease 20%
Cancer 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 57 6,161 $1,775
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 60 139 $776
Injection, methylprednisolone acetate, 40 mg J1030 Office 17 36 $121
Injection, methylprednisolone acetate, 1 mg J1010 Office 27 69 $7

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

39 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record